Dr Sørensen

Biography

Dr Sørensen is a co-founder of Acesion Pharma and from 2011-2016 led the company as CEO, successfully raising funding from Danish and international investors, including Novo A/S, Broadview Ventures (US) and Wellcome Trust (UK), the latter as an SDDI Award in 2013 and a Translational Award in 2016. Ulrik Sørensen has 15+ years of experience from pharma and biotech and holds a PhD in medicinal chemistry and a management degree in organization and strategic management from Copenhagen Business School. He has international research experience from the UK, US and Switzerland and was from 2002 to 2012 employed at NeuroSearch where he held positions as Head of Medicinal Chemistry and Project Director. He was involved in several of the discovery programs and working across strategic collaborations between biotech and big pharma companies. In particular, he led the SK channel inhibitor program that later formed the basis for Acesion Pharma.

Research Interest

Dr Sørensen is a co-founder of Acesion Pharma and from 2011-2016 led the company as CEO, successfully raising funding from Danish and international investors, including Novo A/S, Broadview Ventures (US) and Wellcome Trust (UK), the latter as an SDDI Award in 2013 and a Translational Award in 2016. Ulrik Sørensen has 15+ years of experience from pharma and biotech and holds a PhD in medicinal chemistry and a management degree in organization and strategic management from Copenhagen Business School. He has international research experience from the UK, US and Switzerland and was from 2002 to 2012 employed at NeuroSearch where he held positions as Head of Medicinal Chemistry and Project Director. He was involved in several of the discovery programs and working across strategic collaborations between biotech and big pharma companies. In particular, he led the SK channel inhibitor program that later formed the basis for Acesion Pharma.